Increased complement consumption in musk-antibody-positive myasthenia gravis patients

Medical Principles and Practice

Volumn 20, Issue 6, 2011, Pages 581-583

  Tüzün, Erdem ^a   Yilmaz, Vuslat ^a   Parman, Yeşim ^a   Oflazer, Piraye ^a   Deymeer, Feza ^a   Saruhan Direskeneli, Güher ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Acetylcholine receptor; Alternative pathway; Antibody; Complement system; Muscle specific receptor tyrosine kinase; Myasthenia gravis

Indexed keywords

ANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; COMPLEMENT; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4D; MUSCLE SPECIFIC RECEPTOR TYROSINE KINASE ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT SYSTEM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MYASTHENIA GRAVIS; NEUROPATHOLOGY; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGEN-ANTIBODY REACTIONS; AUTOANTIBODIES; CASE-CONTROL STUDIES; CHILD; COMPLEMENT ACTIVATION; COMPLEMENT C3B; COMPLEMENT C4A; COMPLEMENT FACTOR B; COMPLEMENT SYSTEM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; YOUNG ADULT;

EID: 80053999098     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000330031     Document Type: Article

References (7)

1. Romi F, Kristoffersen EK, Aarli JA, Gilhus NE: The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo. J Neuroimmunol 2005; 158: 191-194. (Pubitemid 39626086)
2. Liu A, Lin H, Liu Y, Cao X, Wang X, Li Z: Correlation of C3 level with severity of generalized myasthenia gravis. Muscle Nerve 2009; 40: 801-808.
3. Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, Tsujihata M, Vincent A, Eguchi K: Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005; 57: 289-293. (Pubitemid 40179868)
4. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A: IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008; 131: 1940-1952. (Pubitemid 351957451)
5. Aggarwal A, Bhardwaj A, Alam S, Misra R: Evidence for activation of the alternate complement pathway in patients with juvenile rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 189-192. (Pubitemid 30139354)
6. Plested CP, Tang T, Spreadbury I, Littleton ET, Kishore U, Vincent A: AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology 2002; 59: 1682-1688. (Pubitemid 35424446)
7. Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S, Scuderi F, Bartoccioni E: Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann NY Acad Sci 2008; 1132: 76-83. (Pubitemid 351841355)